Register entryShortage reported
- Registered sites
- 8
- Active NDC listings
- 4
- Live patents
- 164
- Exclusivities
- 9
- Shortage listings
- 2
- Countries
- 4
- Base
- United States
Authorisation
Registered operations
Analytical testing8Active ingredient (API) manufacture4Labelling5Finished drug manufacture5Packaging5
Sites
Registered establishments
8| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Celgene International SarlRegistrant: Bristol Myers Squibb Company | Route de Perreux 1, Boudry, 2017, Switzerland (CHE) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3006323509482484545 |
| Bristol-Myers Squibb Pharmaceuticals LimitedRegistrant: Bristol Myers Squibb Company | Reeds Lane, Moreton, Wirral CH46 1QW, United Kingdom (GBR) | Analytical testing | 3002806602213617645 |
| Swords Laboratories Unlimited CompanyRegistrant: Bristol Myers Squibb Company | Cruiserath Road, Mulhuddart, D15 H6EF, Ireland (IRL) | Analytical testing, Active ingredient (API) manufacture | 3004531790985104752 |
| Juno Therapeutics, Inc.Registrant: Bristol Myers Squibb Company | 1522 217th Pl, SE, Bothell, Washington (WA) 98021, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3011834594079941307 |
| Bristol-Myers Squibb CompanyRegistrant: Bristol Myers Squibb Company | 38 Jackson Road, Devens, Massachusetts (MA) 01434, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3008455069860967566 |
| Bristol-Myers Squibb Holdings Pharma, Ltd. Liability CompanyRegistrant: Bristol Myers Squibb Company | Road 686, Km 2.3, Manati, Puerto Rico (PR) 00674, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 2650089090413568 |
| CELGENE CORPORATIONRegistrant: Bristol Myers Squibb Company | 556 MORRIS AVE, SUMMIT, New Jersey (NJ) 07901, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3004991673080392427 |
| Juno Therapeutics, Inc.Registrant: Bristol Myers Squibb Company | 400 Dexter Avenue, Seattle, Washington (WA) 98109, United States (USA) | Analytical testing | 3010932912079290042 |
Alert
Drug shortage listings
2| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Azacitidine InjectionOncology | Vidaza, Injection, 100 mg (NDC 59572-102-01) | Current | Available | 18 Dec 20202 Oct 2026 |
| Atazanavir Sulfate; Cobicistat TabletAntiviral | Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11) | To Be Discontinued | - | 3 Nov 20253 Nov 2025 |
Catalogue
Drug listings by form and route
44 active NDC listings: 4 bulk ingredient. By marketing category: BULK INGREDIENT 4.
| Dosage form | NDCs |
|---|---|
| injection | 2 |
| injection, powder, lyophilized, for solution | 2 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| bristol-myers squibb company | 4 |
Exclusivity
Patents and exclusivities
164| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 6967208 | ELIQUIS SPRINKLEapixaban | substance, product | Nov 2026 |
| 7825246 | INREBICfedratinib hydrochloride | substance | Dec 2026 |
| 8034375*PED | ABRAXANEpaclitaxel | use | Feb 2027 |
| 7465800 | REVLIMIDlenalidomide | substance, product | Apr 2027 |
| 6967208*PED | ELIQUIS SPRINKLEapixaban | use | May 2027 |
| 8900566 | DAKLINZAdaclatasvir dihydrochloride | use | Aug 2027 |
| 9421192 | DAKLINZAdaclatasvir dihydrochloride | substance | Aug 2027 |
| 8642025 | DAKLINZAdaclatasvir dihydrochloride | substance, product | Aug 2027 |
| 8741929 | REVLIMIDlenalidomide | use | Mar 2028 |
| 8138199 | INREBICfedratinib hydrochloride | use | Jun 2028 |
| 11571436 | ONUREGazacitidine | product | May 2029 |
| 12053482 | ONUREGazacitidine | use | May 2029 |
| 8796318 | ZEPOSIAozanimod hydrochloride | substance, product | May 2029 |
| 9382217 | ZEPOSIAozanimod hydrochloride | use | May 2029 |
| 8329159 | DAKLINZAdaclatasvir dihydrochloride | substance | Jul 2029 |
| 8148374 | EVOTAZatazanavir sulfate; cobicistat | substance, product | Sept 2029 |
| 10555939 | POMALYSTpomalidomide | product | May 2030 |
| 9993467 | POMALYSTpomalidomide | product | May 2030 |
| 8846628 | ONUREGazacitidine | product | Jun 2030 |
| 10610125 | IDHIFAenasidenib mesylate | use | Jun 2030 |
| 10238643 | COBENFYtrospium chloride; xanomeline tartrate | product | Jul 2030 |
| 10265311 | COBENFYtrospium chloride; xanomeline tartrate | use | Jul 2030 |
| 10369143 | COBENFYtrospium chloride; xanomeline tartrate | use | Jul 2030 |
| 10369144 | COBENFYtrospium chloride; xanomeline tartrate | product | Jul 2030 |
| 10695339 | COBENFYtrospium chloride; xanomeline tartrate | use | Jul 2030 |
| 10239846 | ZEPOSIAozanimod hydrochloride | use | Nov 2030 |
| 10555939*PED | POMALYSTpomalidomide | use | Nov 2030 |
| 9993467*PED | POMALYSTpomalidomide | use | Nov 2030 |
| 8629171 | DAKLINZAdaclatasvir dihydrochloride | substance, product | Jun 2031 |
| 8828427 | POMALYSTpomalidomide | substance, product | Jun 2031 |
| 7528143 | INREBICfedratinib hydrochloride | substance, product | Nov 2031 |
| 8828427*PED | POMALYSTpomalidomide | use | Dec 2031 |
| 9393318 | ABRAXANEpaclitaxel | use | Mar 2032 |
| 9597409 | ABRAXANEpaclitaxel | use | Mar 2032 |
| 10391094 | INREBICfedratinib hydrochloride | product | Jun 2032 |
| 9393318*PED | ABRAXANEpaclitaxel | use | Sept 2032 |
| 9597409*PED | ABRAXANEpaclitaxel | use | Sept 2032 |
| 10039718 | EVOTAZatazanavir sulfate; cobicistat | product | Oct 2032 |
| 10294215 | IDHIFAenasidenib mesylate | product | Jan 2033 |
| 9512107 | IDHIFAenasidenib mesylate | substance, product | Jan 2033 |
| 8481573 | ZEPOSIAozanimod hydrochloride | substance, product | Mar 2033 |
| 10000480 | SOTYKTUdeucravacitinib | substance, product | Nov 2033 |
| 11021475 | SOTYKTUdeucravacitinib | use | Nov 2033 |
| RE47929 | SOTYKTUdeucravacitinib | substance, product | Nov 2033 |
| 9511046 | ABRAXANEpaclitaxel | use | Jan 2034 |
| 9585883 | CAMZYOSmavacamten | use | Jun 2034 |
| 9511046*PED | ABRAXANEpaclitaxel | use | Jul 2034 |
| 10093654 | IDHIFAenasidenib mesylate | substance, product | Aug 2034 |
| 9738625 | IDHIFAenasidenib mesylate | substance | Aug 2034 |
| 9732062 | IDHIFAenasidenib mesylate | substance | Sept 2034 |
| RE50634 | AUGTYROrepotrectinib | substance, product | Jan 2035 |
| RE50050 | CAMZYOSmavacamten | substance, product | Apr 2036 |
| 10294242 | AUGTYROrepotrectinib | substance | Jul 2036 |
| 12187739 | AUGTYROrepotrectinib | product | Jul 2036 |
| 12310968 | AUGTYROrepotrectinib | use | Jul 2036 |
| 11452725 | AUGTYROrepotrectinib | use | Jul 2036 |
| 10689377 | KRAZATIadagrasib | substance, product | May 2037 |
| 11680050 | ZEPOSIAozanimod hydrochloride | substance, product | Sept 2038 |
| 11400092 | INREBICfedratinib hydrochloride | use | Sept 2039 |
| 10925832 | COBENFYtrospium chloride; xanomeline tartrate | product | Sept 2039 |
| Product | Exclusivity | Until |
|---|---|---|
| AUGTYROREPOTRECTINIB | ODE-483 Orphan drug | Jun 2031 |
| CAMZYOSMAVACAMTEN | ODE-398 Orphan drug | Apr 2029 |
| COBENFYTROSPIUM CHLORIDE; XANOMELINE TARTRATE | NCE New chemical entity | Sept 2029 |
| ELIQUIS SPRINKLEAPIXABAN | PED Paediatric | Oct 2028 |
| KRAZATIADAGRASIB | ODE-352 Orphan drug | Dec 2029 |
| ONUREGAZACITIDINE | ODE-320 Orphan drug | Sept 2027 |
| POMALYSTPOMALIDOMIDE | PED Paediatric | Nov 2027 |
| SOTYKTUDEUCRAVACITINIB | I-986 New indication | Mar 2029 |
| ZEPOSIAOZANIMOD HYDROCHLORIDE | M-309 Miscellaneous | Aug 2027 |
Catalogue
Marketed products
4| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | NIVOLUMAB | injection | 70409-7125BULK INGREDIENT |
| - | RELATLIMAB | injection | 70409-7126BULK INGREDIENT |
| - | abatacept | injection, powder, lyophilized, for solution | 70409-2187BULK INGREDIENT |
| - | elotuzumab | injection, powder, lyophilized, for solution | 70409-2291BULK INGREDIENT |
Neighbours
Registered in the same town
8- Cardinal Health 418, Inc.Seattle, WA
- Patheon Manufacturing Services LLCManati, PR
- Pfizer IncBothell, WA
- AGC Biologics, Inc.Bothell, WA
- Veranova, L.P.Devens, MA
- NorMedSeattle, WA
- Seattle Children's HospitalBothell, WA
- ZUVCHEM LLCSummit, NJ
Compare
Comparable companies in United States
- Haleon US Holdings LLC8 sites · 405 NDC
- Genentech, Inc.8 sites · 93 NDC
- Arcet Equipment Company dba Arc3 Gases North8 sites · 3 NDC
- Kenvue Brands LLC7 sites · 564 NDC
- Hospira, Inc.7 sites · 332 NDC
- Allergan, Inc.7 sites · 187 NDC
- Reckitt Benckiser LLC7 sites · 174 NDC
- Amgen, Inc9 sites · 105 NDC
- AGC Biologics, Inc.7 sites · 12 NDC
- Central-McGowan, Inc.7 sites · 2 NDC
Enquiry
Common questions
- Is Bristol Myers Squibb Company FDA approved?
- Bristol Myers Squibb Company holds 8 FDA-registered establishments across 4 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Bristol Myers Squibb Company's drugs manufactured?
- At registered sites in Switzerland, the United Kingdom, Ireland, the United States. The FDA register lists Boudry; Moreton; Mulhuddart; Bothell, WA; Devens, MA; Manati, PR, and 2 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does Bristol Myers Squibb Company make?
- 4 products are listed under Bristol Myers Squibb Company in the openFDA NDC Directory, most often as injection; injection, powder, lyophilized, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
- Are any Bristol Myers Squibb Company products in shortage?
- 1 presentation is currently listed in the FDA drug shortage database under Bristol Myers Squibb Company, covering Azacitidine Injection.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.